Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer

References

• Brambilla E, Travis WD. Lung cancer. In: Stewart BW, Wild CP, editors. World cancer report. Lyon: WHO; 2014:350–361.
   Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Glassberg AB, Cornett P. Lung: non-small cell. In: Dollinger M, Rosenbaum EH, Cable G, editors. Everyone's guide to cancer therapy. Kansas City, MO: Somerville House Books Limited; 1994. p. 469–475.
   Google Scholar
• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594.
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13:5–13.
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC. Overview of the initial treatment of advanced non-small cell lung cancer. In: West HJ, editor. UpToDate. 2019. Topic 4607, Version 60.0.
   Google Scholar
• Soejima K, Naoki K, Ishioka K, et al. A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2015;75:513–519.
   PubMed Web of Science ®Google Scholar
• Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii27–iii39.
   PubMed Web of Science ®Google Scholar
• Kelly K, Crowley J, Bunn PA, Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. JCO. 2001;19:3210–3218.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301.
   PubMed Web of Science ®Google Scholar
• Schulze AB, Schmidt LH. PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. J Thorac Dis. 2017;9:E384–E386.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Hellmann MD, Paz-Ares LG, et al. Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. JCO. 2018;36:9001–9001.
   Web of Science ®Google Scholar
• Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. JCO. 2018;36:LBA4–LBA4.
   Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376:2415–2426.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98.
   PubMed Web of Science ®Google Scholar
• Ichiki M, Gohara R, Fujiki R, et al. Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003;52:67–72.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Sugawara S, et al. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801. Oncologist. 2014;19:352–353.
   PubMed Web of Science ®Google Scholar
• Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079–1088.
   PubMed Web of Science ®Google Scholar
• Volk V, Cathomas R, Mark M, et al. Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience. Support Care Cancer. 2016;24:2119–2128.
   PubMed Web of Science ®Google Scholar
• Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211–218.
   PubMed Web of Science ®Google Scholar
• Warburg OK. Uber den Stoffwechsel der Carcinomzelle [About the metabolism of the carcinoma cell]. Biochem Z. 1924;152:309–344.
   Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123:309–314.
   PubMed Web of Science ®Google Scholar
• Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab (Lond). 2010;7:7.
   PubMed Web of Science ®Google Scholar
• Iyikesici MS, Slocum A, Turkmen E, et al. Long-term outcomes of the treatment of unresectable (Stage III - IV) ductal pancreatic adenocarcinoma using metabolically supported chemotherapy (MSCT): a retrospective study. JOP. 2015;17:36–41.
   Web of Science ®Google Scholar
• Iyikesici MS, Slocum A, Turkmen E, et al. Complete response of locally advanced (stage III) rectal cancer to metabolically supported chemoradiotherapy with hyperthermia. Int J Cancer Res Mol Mech. 2016;2:1–4.
   Google Scholar
• Iyikesici MS, Slocum AK, Slocum A, et al. Efficacy of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy for stage IV triple-negative breast cancer. Cureus. 2017;9:e1445.
   PubMed Web of Science ®Google Scholar
• Ayre SG, Garcia y, Bellon DP, Garcia DP. Jr. Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer. Med Hypotheses. 2000;55:330–334.
   PubMed Web of Science ®Google Scholar
• Seyfried TN, Flores R, Poff AM, et al. Metabolic therapy: a new paradigm for managing malignant brain cancer. Cancer Lett. 2015;356:289–300.
   PubMed Web of Science ®Google Scholar
• Stafford P, Abdelwahab MG, Kim DY, et al. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond). 2010;7:74.
   PubMed Web of Science ®Google Scholar
• Masko EM, Thomas JA, 2nd, Antonelli JA, et al. Low-carbohydrate diets and prostate cancer: how low is "low enough"? Cancer Prev Res (Phila). 2010;3:1124–1131.
   PubMed Web of Science ®Google Scholar
• Zuccoli G, Marcello N, Pisanello A, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab (Lond). 2010;7:33.
   PubMed Web of Science ®Google Scholar
• Zhou W, Mukherjee P, Kiebish MA, et al. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond). 2007;4:5.
   PubMed Web of Science ®Google Scholar
• Poff AM, Ari C, Seyfried TN, et al. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One. 2013;8:e65522.
   PubMed Web of Science ®Google Scholar
• Poff AM, Ward N, Seyfried TN, et al. Non-toxic metabolic management of metastatic cancer in VM Mice: novel combination of ketogenic diet, ketone supplementation, and hyperbaric oxygen therapy. PLoS One. 2015;10:e0127407.
   PubMed Web of Science ®Google Scholar
• Ohguri T, Imada H, Narisada H, et al. Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results. Int J Hyperthermia. 2009;25:160–167.
   PubMed Web of Science ®Google Scholar
• Ohguri T, Kunugita N, Yahara K, et al. Efficacy of hyperbaric oxygen therapy combined with mild hyperthermia for improving the anti-tumour effects of carboplatin. Int J Hyperthermia. 2015;31:643–648.
   PubMed Web of Science ®Google Scholar
• Xu MJ, Alberts DS. Potentiation of platinum analogue cytotoxicity by hyperthermia. Cancer Chemother Pharmacol. 1988;21:191–196.
   PubMed Web of Science ®Google Scholar
• Herman TS, Teicher BA, Chan V, et al. Effect of heat on the cytotoxicity and interaction with DNA of a series of platinum complexes. Int J Radiat Oncol Biol Phys. 1989;16:443–449.
   PubMed Web of Science ®Google Scholar
• Othman T, Goto S, Lee JB, et al. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology. 2001;62:208–212.
   PubMed Web of Science ®Google Scholar
• Cividalli A, Cruciani G, Livdi E, et al. Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma. Int J Radiat Oncol Biol Phys. 1999;44:407–412.
   PubMed Web of Science ®Google Scholar
• Zoul Z, Filip S, Melichar B, et al. Weekly paclitaxel combined with local hyperthermia in the therapy of breast cancer locally recurrent after mastectomy–a pilot experience. Oncol Res Treat. 2004;27:385–388.
   Web of Science ®Google Scholar
• Moyer HR, Delman KA. The role of hyperthermia in optimizing tumor response to regional therapy. Int J Hyperthermia. 2008;24:251–261.
   PubMed Web of Science ®Google Scholar
• Jones EL, Samulski TV, Vujaskovic Z, et al. Hyperthermia. In: Perez CA, Brady LW, Halperin WC, et al. editors. Principles and practice of radiation oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 699–735.
   Google Scholar
• Wouters BG, van den BT, Magagnin MG, et al. Targeting hypoxia tolerance in cancer. Drug Resist Updat. 2004;7:25–40.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. MO. 2001;18:243–259.
   Web of Science ®Google Scholar
• Hoogsteen IJ, Marres HA, van der Kogel AJ, et al. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. Clin Oncol (R Coll Radiol). 2007;19:385–396.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Meth Enzymol. 2004;381:335–354.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004;9:4–9.
   PubMed Web of Science ®Google Scholar
• Stuhr LE, Raa A, Oyan AM, et al. Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats. J Neurooncol. 2007;85:191–202.
   PubMed Web of Science ®Google Scholar
• Moen I, Oyan AM, Kalland KH, et al. Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model. PLoS One. 2009;4:e6381.
   PubMed Web of Science ®Google Scholar
• Stuhr LE, Iversen VV, Straume O, et al. Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors. Cancer Lett. 2004;210:35–40.
   PubMed Web of Science ®Google Scholar
• Petre PM, Baciewicz FA, Jr., Tigan S, et al. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model. J Thorac Cardiovasc Surg. 2003;125:85–95; discussion 95.
   PubMed Web of Science ®Google Scholar
• Al-Waili NS, Butler GJ, Beale J, et al. Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy. Med Sci Monit. 2005;11:RA279–RA289.
   PubMed Web of Science ®Google Scholar
• Bennett M, Feldmeier J, Smee R, et al. Hyperbaric oxygenation for tumour sensitisation to radiotherapy: a systematic review of randomised controlled trials. Cancer Treat Rev. 2008;34:577–591.
   PubMed Web of Science ®Google Scholar
• Schwartz LH, Litiere S, de Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–137.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE): National Cancer Institute; 2010 [cited 2018 July 23]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
   Google Scholar
• Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. JCO. 2003;21:2933–2939.
   PubMed Web of Science ®Google Scholar
• Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. JCO. 2008;26:468–473.
   PubMed Web of Science ®Google Scholar
• Schuette W, Blankenburg T, Guschall W, et al. Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer. 2006;7:338–343.
   PubMed Web of Science ®Google Scholar
• Liu SV, Camidge DR, Gettinger SN, et al. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018;101:114–122.
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49: 24S–42S.
   PubMed Web of Science ®Google Scholar
• Frezza C, Pollard PJ, Gottlieb E. Inborn and acquired metabolic defects in cancer. J Mol Med. 2011;89:213–220.
   PubMed Web of Science ®Google Scholar
• Bayley JP, Devilee P. The Warburg effect in 2012. Curr Opin Oncol. 2012;24:62–67.
   PubMed Web of Science ®Google Scholar
• Shinitzky M, Henkart P. Fluidity of cell membranes-current concepts and trends. Int Rev Cytol. 1979;60:121–147.
   PubMedGoogle Scholar
• Demetrius LA, Coy JF, Tuszynski JA. Cancer proliferation and therapy: the Warburg effect and quantum metabolism. Theor Biol Med Model. 2010;7:2.
   PubMed Web of Science ®Google Scholar
• Schilsky RL, Bailey BD, Chabner BA. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharmacol. 1981;30:1537–1542.
   PubMed Web of Science ®Google Scholar
• Gasparro FP, Krobler RM, Yemul SS, et al. Receptor-mediated photo-cytotoxicity: synthesis of a photoactivatable psoralen derivative conjugated to insulin. Biochem Biophys Res Commun. 1986;141:502–509.
   PubMed Web of Science ®Google Scholar
• Yoshimasa Y, Namba Y, Hanaoka M, et al. A new approach to the detection of autoantibodies against insulin receptors that inhibit the internalization of insulin into human cells. Diabetes. 1984;33:1051–1054.
   PubMed Web of Science ®Google Scholar
• Poznansky MJ, Singh R, Singh B, et al. Insulin: carrier potential for enzyme and drug therapy. Science. 1984;223:1304–1306.
   PubMed Web of Science ®Google Scholar
• Jeffcoat R. The biosynthesis of unsaturated fatty acids and its control in mammalian liver. Essays Biochem. 1979;15:1–36.
   PubMedGoogle Scholar
• Papa V, Pezzino V, Costantino A, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest. 1990;86:1503–1510.
   PubMed Web of Science ®Google Scholar
• Yee D. The insulin-like growth factors and breast cancer-revisited. Breast Cancer Res Treat. 1998;47:197–199.
   PubMed Web of Science ®Google Scholar
• Gross GE, Boldt DH, Osborne CK. Perturbation by insulin of human breast cancer cell cycle kinetics. Cancer Res. 1984;44:3570–3575.
   PubMed Web of Science ®Google Scholar
• Toth C, Clemens Z. Halted progression of soft palate cancer in a patient treated with the paleolithic ketogenic diet alone: a 20-months follow-up. Am J Med Case Rep. 2016;4:288–292.
   Google Scholar
• Schmidt M, Pfetzer N, Schwab M, et al. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab (Lond). 2011;8:54.
   PubMed Web of Science ®Google Scholar
• Rieger J, Bahr O, Maurer GD, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44:1843–1852.
   PubMed Web of Science ®Google Scholar
• Seyfried TN. Case studies and personal experiences in using the ketogenic diet for cancer management, in cancer as a metabolic disease: on the origin, management and prevention of cancer. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2012.
   Google Scholar
• Fine EJ, Segal-Isaacson CJ, Feinman RD, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition. 2012;28:1028–1035.
   PubMed Web of Science ®Google Scholar
• Champ CE, Palmer JD, Volek JS, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol. 2014;117:125–131.
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, et al. Ketone body utilization drives tumor growth and metastasis. Cell Cycle. 2012;11:3964–3971.
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Prisco M, Ertel A, et al. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle. 2011;10:1271–1286.
   PubMed Web of Science ®Google Scholar
• Bonuccelli G, Tsirigos A, Whitaker-Menezes D, et al. Ketones and lactate "fuel" tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle. 2010;9:3506–3514.
   PubMed Web of Science ®Google Scholar
• Tisdale MJ, Brennan RA. Loss of acetoacetate coenzyme A transferase activity in tumours of peripheral tissues. Br J Cancer. 1983;47:293–297.
   PubMed Web of Science ®Google Scholar
• Sawai M, Yashiro M, Nishiguchi Y, et al. Growth-inhibitory effects of the ketone body, monoacetoacetin, on human gastric cancer cells with succinyl-CoA: 3-oxoacid CoA-transferase (SCOT) deficiency. Anticancer Res. 2004;24:2213–2217.
   PubMed Web of Science ®Google Scholar
• Maurer GD, Brucker DP, Bahr O, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011;11:315.
   PubMed Web of Science ®Google Scholar
• Skinner R, Trujillo A, Ma X, et al. Ketone bodies inhibit the viability of human neuroblastoma cells. J Pediatr Surg. 2009;44:212–216. discussion 216.
   PubMed Web of Science ®Google Scholar
• Klement RJ, Champ CE, Otto C, et al. Anti-tumor effects of ketogenic diets in mice: a meta-analysis. PLoS One. 2016;11:e0155050.
   PubMed Web of Science ®Google Scholar
• Magee BA, Potezny N, Rofe AM, et al. The inhibition of malignant cell growth by ketone bodies. Aust J Exp Biol Med Sci. 1979;57:529–539.
   PubMedGoogle Scholar
• Poff AM, Ari C, Arnold P, et al. Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. Int J Cancer. 2014;135:1711–1720.
   PubMed Web of Science ®Google Scholar
• Abdelwahab MG, Fenton KE, Preul MC, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One. 2012;7:e36197.
   PubMed Web of Science ®Google Scholar
• Schwartz K, Chang HT, Nikolai M, et al. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab. 2015;3:3.
   PubMed Web of Science ®Google Scholar
• Woolf EC, Scheck AC. The ketogenic diet for the treatment of malignant glioma. J Lipid Res. 2015;56:5–10.
   PubMed Web of Science ®Google Scholar
• Seyfried TN, Yu G, Maroon JC, et al. Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. Nutr Metab (Lond). 2017;14:19.
   PubMed Web of Science ®Google Scholar